Study of BCL-2 inhibitor treatments for chronic lymphocytic leukemia
This study looks at real-world experiences of people with chronic lymphocytic leukemia (CLL) who have used or are using a type of targeted therapy called a BCL-2 inhibitor. It aims to understand how well these treatments work and their side effects in everyday practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- You have received or are currently receiving treatment with a BCL-2 inhibitor (like venetoclax).
- Your medical records have key information (like your diagnosis details and lab tests) and at least one follow-up visit after starting treatment to check how you're doing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
This study tests a new targeted drug (DZD8586) in combination with other therapies for people who have just been diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and have not yet received any treatment. The goal is to see if this combination works better than current standard treatments.
This study looks at how health-related quality of life changes in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when starting a new treatment. The goal is to better understand what affects well-being during therapy.
This study looks at what happens to patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after they stop taking a type of targeted therapy called a BTK inhibitor. It aims to understand treatment patterns and outcomes to help guide future care.
This study follows patients with chronic lymphocytic leukemia (CLL)—a blood cancer—who are starting treatment with two drugs called ibrutinib and venetoclax together for a set period of time. Researchers want to understand how well this treatment works and how it affects patients' daily lives in real-world settings, rather than in a controlled lab environment.
This study looks at how well a type of targeted therapy called a BTK inhibitor works for people with chronic lymphocytic leukemia (CLL), a cancer of the blood and bone marrow. It includes both people who have never been treated and those whose cancer came back or didn't get better. The goal is to understand real-world outcomes and help guide future care.
Hear when a new CLL/SLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.